20
Participants
Start Date
December 31, 2010
Primary Completion Date
December 31, 2011
Study Completion Date
May 31, 2012
Dysport
"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
Perlane L
The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
Kenneth R. Beer, M.D., PA, West Palm Beach
Collaborators (1)
Medicis Pharmaceutical Corporation
INDUSTRY
Beer, Kenneth R., M.D., PA
INDIV